Interventional cardiologist details key breakthroughs in tricuspid valve replacement and repair

Interventional cardiologist details key breakthroughs in tricuspid valve replacement and repair

0
2024 has been a banner year for structural heart treatments, especially those focused on the tricuspid valve. In February, for example, Edwards Lifesciences made...
Scientists say drug breakthrough could be 'new era' for cancer treatment

Scientists say drug breakthrough could be 'new era' for cancer treatment

0
A study has discovered that blocking an enzyme in the body's cells which senses changes in oxygen levels could stop the disease from progressing...
LSD D-Tartrate Receives Breakthrough Therapy Designation From FDA for Generalized Anxiety Disorder

LSD D-Tartrate Receives Breakthrough Therapy Designation From FDA for Generalized Anxiety...

0
The FDA has granted breakthrough therapy designation (BTD) to lysergide (LSD) d-tartrate (MM-120; Mind Medicine ) for the treatment of generalized anxiety disorder (GAD)....
Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China

Clearmind Medicine’s Psychedelic Treatment Granted Divisional Patent Approval in China

0
A Novel Approach to Combatting Binge Behaviors with Groundbreaking Psychedelic TherapyTel Aviv, Israel / Vancouver, Canada, March 19, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine...
Express & Star

Scientists hopeful for ‘new era’ of blood cancer treatment after breakthrough

0
A drug breakthrough could usher in a “new era” for how an aggressive form of blood cancer is treated, scientists have said.Described by researchers...
Drug breakthrough could usher in 'new era' for blood cancer treatment

Drug breakthrough could usher in ‘new era’ for blood cancer treatment

0
Scientists have discovered a promising new drug therapy for an aggressive form of leukaemia, raising hopes of a "new era" for the treatment of...
FDA Grants Breakthrough Designation to MM120 for Anxiety

FDA Grants Breakthrough Designation to MM120 for Anxiety

0
Announced on March 7, 2024, the US Food and Drug Administration (FDA) granted MindMed a breakthrough therapy designation for MM120 (lysergide d-tartrate) for generalized...
Relapsed/Refractory Multiple Myeloma Treatment Advances With Three BiTE Therapy Options

Relapsed/Refractory Multiple Myeloma Treatment Advances With Three BiTE Therapy Options

0
By the end of 2023, there were 3 bispecific T-cell engagers (BiTEs) that had been FDA-approved for the treatment of relapsed/refractory (R/R) multiple myeloma...

Recent Posts